© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
October 13, 2022
Sheela Tejwani, MD, highlights some exciting recent trial data and shares clinical pearls for community oncologists treating mCSPC.
An expert oncologist describes her approaches to treating patients with castration-sensitive prostate cancer and low-volume metastatic disease.
Dr Tejwani lists the frontline treatment options currently available for mCSPC and reviews the chosen treatment regimen in the presented patient case.
Sheela Tejwani, MD, presents the case of an 83-year-old man with mCSPC, and shares her first impressions as compared to her typical patients.